Articles On Immutep (ASX:IMM)

Title Source Codes Date
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead IMM 3 hours ago
Immutep (ASX:IMM) share price slips amid trial safety update

The Immutep Ltd (ASX: IMM) share price is in the red this morning, down 1.05% at the time of writing to 47 cents. The biotech company is developing LAG-3 related immunotherapy treatments for patients with cancer and autoimmune disease. Bel...

Motley Fool IMM 6 days ago
Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated the first five patients in its study evaluating eftilagimod alpha (efti) in conjunction with standard of care chemotherapy  No additional safety signs were observed during the study, which is the first time a trip...

themarketherald.com.au IMM 6 days ago
Market Highlights and 5 ASX Small Caps to watch on Thursday

Wall Street falls further on Omicron fears The US stock markets once again fell heavily overnight, as the US confirmed its first case of the omicron variant. Cases of omicron in South Africa have doubled in two days, with the new strain als...

Stockhead IMM 1 week ago
ScoPo’s Powerplays: Christmas rally runs out of puff, but market awaits crucial release from Neuren

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Stockhead IMM 1 week ago
Trading Places: Which recent ASX IPO saw investees top up their holdings on market?

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Stockhead IMM 1 week ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead IMM 2 weeks ago
ScoPo’s Powerplays: Investors look to Healthcare for ESG exposure, and Volpara is the poster child

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Stockhead IMM 2 weeks ago
Immutep (ASX:IMM) completes Phase II recruitment

Immutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer The last patient has now been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study Patients are now participating across three p...

themarketherald.com.au IMM 2 weeks ago
ASX Health Stocks: Apiam and Trajan on acquisition trail, while Immutep starts Phase 2 trials

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is up by 0.30%. Immutep Limited (ASX:IMM) has has successfully completed patient recruitment for the Phase II TACTI-002 study of LAG-3...

Stockhead IMM 2 weeks ago
Market Highlights and 5 ASX Small Caps to watch on Friday

Tech stocks gain on Wall Street US stocks were mixed overnight, but investors’ appetite were mainly focused on the tech sector. The Dow Jones retreated 0.17% , but the S&P 500 was up 0.34%, and tech heavy Nasdaq by 0.45%. Megatech stock...

Stockhead IMM 2 weeks ago
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

Stockhead IMM 3 weeks ago
Market Highlights and 5 ASX Small Caps to watch on Monday

Wall Street was lower for the week US stocks rebounded on Friday, but finished the week lower after an inflation data-triggered selloff on Wednesday. All three US stocks benchmarks rose, led by tech – the Dow Jones by 0.5%, the S&P 500...

Stockhead IMM 3 weeks ago
ScoPo’s Powerplays: AGM season ‘flushes out negative surprises’ but creates buying opportunities

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The AGM sea...

Stockhead IMM 3 weeks ago
Why big biotechs will have their eyes on Immutep

Despite what Immutep’s two-day sell-off may have you thinking, now is the time the biotech giants are going to do due diligence on Marc Voigt’s LAG-3 bet.

AFR IMM 3 weeks ago
Why Afterpay, Immutep, Pushpay, and Vulcan shares are falling

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is trading lower. At the time of writing, the benchmark index is down 0.1% to 7,425.7 points. Four ASX shares that are falling more than most...

Motley Fool IMM 4 weeks ago
Immutep (ASX:IMM) share price slides 20% despite latest trial results

Shares in Australian biotechnology company Immutep Ltd (ASX: IMM) are tanking on Wednesday morning, down 20% to 56 cents. Immutep shares are on the move this morning after the company announced data from a Phase IIb trial on its lead drug...

Motley Fool IMM 4 weeks ago
10 at 10: These ASX stocks are paying off their investors’ excitement this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead IMM 4 weeks ago
China is about to grant patents like never before, and these ASX stocks have already got some

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

Stockhead IMM 1 month ago
ASX Health Stocks: Intelicare jumps 35pc on AI in-home sensor tech contract for seniors

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

Stockhead IMM 1 month ago
Here’s why the Immutep (ASX:IMM) share price is rising on Tuesday

The Immutep Ltd (ASX: IMM) share price is climbing today after the biotechnology company announced it has secured a new patent. At the time of writing, Immutep shares are edging 1.7% higher to 59.5 cents. In the last month, its shares have...

Motley Fool IMM 1 month ago
Immutep (ASX:IMM) granted Chinese patent

Immutep (IMM) is granted a new patent by the Chinese Patent Office for its lead product candidate, eftilagimod alpha The new patent relates to methods of use of efti in combination with a chemotherapy agent to treat cancer The new Chinese...

themarketherald.com.au IMM 1 month ago
Immutep (ASX:IMM) reports “positive” drug development feedback from EMA

Shares in Immutep (IMM) open green after the company announced positive feedback from European regulators around its lead anti-cancer drug candidate Immutep says the European Medicines Agency (EMA) supported IMM’s continued development of...

themarketherald.com.au IMM 1 month ago
Market Highlights and 5 ASX Small Caps to watch on Friday

Nasdaq at all time high Tech stocks rallied in New York overnight, pushing up the Nasdaq composite index by 1.39% to its highest level ever. The Dow Jones rose by 0.68% and S&P 500 by 0.98% (also at all-time highs), capping off a good d...

Stockhead IMM 1 month ago
Immutep (ASX:IMM) share price hikes amid clinical trial momentum in FY21

Shares in clinical stage biotechnology company Immutep Ltd (ASX: IMM) are inching higher in afternoon trading, up 2.5% to 62 cents apiece. Immutep’s share price has been on the move amid the release of its annual report today, in which...

Motley Fool IMM 1 month ago
MoneyTalks: Here’s why this fund backs these 2 big ASX biotechs alongside Merck and Novavax

MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and analysts are looking at right now and in this edition we’re looking at big biotechs. Today we hear from James McDonald, portfolio manager of Pe...

Stockhead IMM 1 month ago
The Week that Was – October 11-16, 2021

ShareCafeThe Week that Was – October 11-16, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

ShareCafe IMM 1 month ago
Immutep Taking the Fight to Cancer

ShareCafeImmutep Taking the Fight to Cancer In May 2021, Corporate Connect analyst Marc Sinatra published a comprehensive research report on ASX-listed biotech Immutep Ltd (ASX: IMM). So impressed was he with IMM that Corporate Connect felt...

ShareCafe IMM 1 month ago
Market Highlights and 5 ASX Small Caps to watch on Wednesday

Global stocks sell off as bond yields rise All three US stock market benchmark indexes fell sharply overnight, as the 10-year benchmark US Treasury yield continues its rapid climb. The 10-year yield was up by 6 basis points to 1.54%, its hi...

Stockhead IMM 2 months ago
The Immutep (ASX:IMM) share price is up 25% in a month and could go higher

The Immutep Ltd (ASX: IMM) share price is pushing higher again on Monday despite the market decline. At the time of writing, the biotechnology company’s shares are up almost 4% to 55 cents. This means the Immutep share price is now up 25%...

Motley Fool IMM 2 months ago
Immutep with Proactive at the ASX Small and Mid Cap Conference

Proactive Investors IMM 2 months ago
ScoPo’s Powerplays: Profit-taking on the cards for health stocks that have had good runs

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Stockhead IMM 2 months ago
The Week that Was – August 30-September 3, 2021

ShareCafeThe Week that Was – August 30-September 3, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

ShareCafe IMM 3 months ago
ScoPo’s Powerplays: Recent price swings uncovered hidden gems and buying opportunities in healthcare

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week The Healthcar...

Stockhead IMM 3 months ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead IMM 3 months ago
7% Gain for Immutep Shares as it Progresses Clinical Trials (ASX:IMM)

Small-cap biotech stock Immutep [ASX:IMM] is on the up today. Shares are currently trading 7.92% higher at time of writing. Climbing higher thanks to some positive news in relation to the company’s ongoing clinical trials. The post 7% Gain...

MoneyMorning IMM 3 months ago
7% Up For Immutep Share Price — Progresses Clinical Trials (ASX:IMM)

Small-cap biotech stock Immutep Ltd [ASX:IMM] is on the up today. The IMM share price is currently trading 7.92% higher at time of writing... The post 7% Up For Immutep Share Price — Progresses Clinical Trials (ASX:IMM) appeared first on M...

MoneyMorning IMM 3 months ago
Why BlueBet, Dicker Data, Immutep, & Sandfire are charging higher

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is off its intraday lows but still trading lower. At the time of writing, the benchmark index is down 0.3% to 7,513.5 points. Four ASX shares that are not letting that hold them back...

Motley Fool IMM 3 months ago
Why the Immutep (ASX:IMM) share price is leaping 5% today

The Immutep Ltd (ASX: IMM) share price is gaining today following news of the company’s Two ACTive Immunotherapies (TACTI-002) trial. Recruitment for the trial’s stage 2 of part B is now officially complete. Right now, the Immutep share pr...

Motley Fool IMM 3 months ago
Immutep Leading the development of immunotherapy for cancer and autoimmune diseases

ShareCafeImmutep Leading the development of immunotherapy for cancer and autoimmune diseases   Fund manager James McDonald at the Pengana High Conviction Equities Fund provides insight into some of the current opportunities arising for the...

ShareCafe IMM 3 months ago
Immutep's Chinese partner to expand 'efti' trial pipeline

Immutep (ASX:IMM) has announced that its Chinese partner for eftilagimod alpha (efti), EOC Pharma, is planning to expand its clinical trial pipeline for the investigative immunotherapy.

BiotechDispatch IMM 3 months ago
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

Stockhead IMM 3 months ago
Closing Bell: ASX closes slightly lower, still notches up weekly gain

The ASX 200 closed at 7,488 points which was 0.04% down from yesterday but up 0.37% from last Friday. The ASX Emerging Companies Index lost 0.57% to close at 2,285 points. The best sector was industrials which gained 1.07%. Tech and consume...

Stockhead IMM 3 months ago
Four ASX healthcare stocks that are on investors’ radar today

Highlights Emyria has entered into a Master Services Agreement with Calvert Labs, a leading North American preclinical contract research organisation. Advanced Human Imaging announced the public filing of a registration statement with...

Kalkine Media IMM 3 months ago
Immutep (ASX:IMM) share price jumps 5% on Chinese patent grant

The Immutep Ltd (ASX: IMM) share price has stepped into the green from the opening of trade on Friday. Immutep shares are on the move as the company announced it had been granted a Chinese patent on one of its antibody molecules. Let’s i...

Motley Fool IMM 3 months ago
Market Highlights and 5 ASX Small Caps to watch on Friday

Wall Street snaps three-day gain streak All three US stock market indexes fell last night, and snapped their streak of gains in the previous three days. The Dow Jones fell by 0.54%, S&P500 by 0.58%, and the tech heavy Nasdaq by 0.64%. F...

Stockhead IMM 3 months ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead IMM 3 months ago
Why Latitude Group and Telstra created a buzz on the ASX today?

Summary  Latitude Group Holdings has cracked a deal for fintech Symple to accelerate business growth. Telstra Health has signed a pact to acquire MedicalDirector to support its vision of becoming a leading partner to the healthcare sec...

Kalkine Media IMM 3 months ago
Trading Places: Who’s betting on return to office stocks?

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Stockhead IMM 4 months ago
Why are Emyria, Pharmaxis, Immutep, and Neuren trending today?

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

Kalkine Media IMM 4 months ago